PVLAPalvella Therapeutics, Inc.
What is the market doing?
No clear lean: nothing decisive, though a crowded short (+18% of shares).
Choppy, but holding above its 200-day average. Price is +14% vs its 200-day average.
Insiders were net sellers over the 90 days ending Oct 8, 2026; selling is often routine (taxes, diversification).
A crowded short, settled Sep 15, 2026, more than a week of normal trading to cover, a crowded exit.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. Insider selling is often routine (taxes, diversification); only cluster buying is a strong tell.
How PVLA is trading
Palvella Therapeutics, Inc. is +139% over the past year while the S&P 500 is +18%: 120 points ahead of the market.
1-year return · S&P 500 +18%
- vs 200-day average
- +14%
vs 200-day average · a clear uptrend
- RSI (14)
- 35
RSI (14) · neutral
- Below its 52-week high
- 12%
Below its 52-week high
Details›
- Last close2026-10-09
- $138.94
- 1 monthS&P 500 +2.7%
- −7.7%
- 1 yearS&P 500 +18%
- +139%
- 5 yearsS&P 500 +88%
- −68%
- vs 50-day average$147.52
- −5.8%
- 52-week high
- $158.19
- 52-week low
- $56.69
- Annualised volatility
- 77%
- Insider buying, net, 6 monthsForms 3/4/5 to 2026-10-08
- −$49K
| Year | Return |
|---|---|
| 2026 (year to date) | +33% |
| 2025 | +772% |
| 2024 | −18% |
| 2023 | −82% |
| 2022 | −72% |
| 2021 | +51% |
| 2020 | −31% |
| 2019 | +36% |
| 2018 | −65% |
| 2017 | +437% |
| Month | Years | Positive | Average |
|---|---|---|---|
| Jan | 10 | 7 of 10 | +10% |
| Feb | 10 | 5 of 10 | +9.5% |
| Mar | 10 | 4 of 10 | −0.22% |
| Apr | 10 | 2 of 10 | −8.5% |
| May | 10 | 5 of 10 | +17% |
| Jun | 10 | 5 of 10 | −5.9% |
| Jul | 11 | 8 of 11 | +16% |
| Aug | 11 | 8 of 11 | +14% |
| Sep | 11 | 4 of 11 | −6.9% |
| Oct | 11 | 4 of 11 | −3.8% |
| Nov | 10 | 5 of 10 | +1.6% |
| Dec | 10 | 4 of 10 | −4.8% |
End-of-day closes from IEX; the S&P 500 comparison uses SPY over the same window. Prices are a reference point, not a basis for trading decisions.
Biotechnology
The closest names by size in the same industry